External open innovation partner programEarly stage research projects for prevention, diagnosis or therapy of Inflammatory Bowel Diseases (IBD)
We are looking for pilot proposals for novel approaches for the prevention, diagnosis, and treatment of Inflammatory Bowel Diseases. The Broad Medical Research Program at CCFA (BMRP-CCFA) will consider funding clinical or translational IBD research projects that:
- Are innovative
- Are in the early stages of exploration
- Will improve diagnosis, therapy or prevention of IBD within the next 3-5 years and
- Will lead to longer-term funding by more traditional granting agencies
Proposals must be clinically relevant and must benefit patients with IBD. BMRP-CCFA especially supports research that can be readily translated to improve the care of human IBD in the near future. Proposals in the basic sciences should have clear relevance to findings and observations in IBD patients. Preference will be given for work conducted with human samples or patients. Research using non-human material should lead to translational benefits for patients with IBD.
Who is eligible: This program is open to researchers working in non-profit, charitable institutions, such as a university, hospital, or research organization. Applications are accepted from institutions worldwide.
Basic, translational and clinical investigators, scientists not currently working in inflammatory bowel disease, and interdisciplinary teams are encouraged to apply.
Furthermore, the applicant who wishes to take on the Principal Investigator position must have a faculty appointment at the institution. For this, we request that the applicant's university or institution (particularly the Grants and Contracts personnel) send us a statement confirming that the applicant is or to apply as a Principal Investigator from his/her institution.
There can be only one Principal Investigator for each proposal, but we encourage multi-investigator, multi-institutional applications.
BMRP-CCFA funding can be requested for up to two years, but grants are funded only one year at a time. If a PI wishes to seek continuation funding, funding for a second year is based upon a satisfactory Progress Report, which will undergo review from the BMRP-CCFA director, and, in some cases, a peer review.
Inclusive of at least 50% or targeted recruitment goals.
The range of annual grant awards is between $13,000 and $175,000, with a mean annual funding per grant of $114,082.
BMRP-CCFA will review your Letter of Interest. Most, but not all Letters of Interest will be peer reviewed. Proposals are reviewed individually by external leading investigators in each research area or topic. Reviews are conducted anonymously to encourage candid comments. Proposals may be approved or rejected based on their merits and how closely they meet the BMRP-CCFA’s objectives.
Reviewers of Letter of Interest will comment on the scientific strength of the proposal, innovative nature of the ideas, strength of the Principal Investigator, co-investiagor, and scientific environment, and will provide suggestions that would improve the project and its chances of helping patients with IBD.
Investigators whose Letters of Interest fit the BMRP-CCFA's criteria and areas of interest will be invited to submit a Full Grant Application. The full grant application should be submitted within 4 weeks after the invitation.
Applicants should submit a brief Letter of Interest (up to three pages, not including attachments) as the initial request for funding.
BMRP-CCFA will not share the information beyond its own staff and reviewers. However, your Letter of Interest should contain only non-confidential information. If your Letters of Interest fit the BMRP-CCFA's criteria and areas of interest, you will be invited to submit a Full Grant Application, and a Confidential Disclosure Agreement will be completed.
Furthermore, grant Application reviewers are required to sign confidentiality agreements prior to receiving the proposals in order to protect the investigators’ ideas.
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
The Crohn's & Colitis Foundation of America (CCFA) is a non-profit, volunteer-driven organization dedicated to finding the cures for Crohn's disease and ulcerative colitis, and to improving the quality of life of children and adults affected by these diseases.
CCFA sponsors basic and clinical research of the highest quality. Since CCFA’s founding five decades ago, the organization has provided more than $267 million, funding the best IBD research anywhere in the world and implementing a peer-review process that ensures that only the most promising and relevant grant applications are funded.
With more than 1,400 grants awarded, CCFA has played a role in every major scientific breakthrough in IBD, from generating data that led to new therapies to the discovery of the first gene for Crohn's disease.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 companies working on 5000 different R&D projects in more than 50 topics, organized in 10 main types of partnering programs with Academia.